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Decreased clearance of low-density lipoprotein in patients with
chronic renal failure
SoHvI HORKKO, KAISA HUTTUNEN, TAINA KORHONEN, and Y. ANTERO KESANIEMI
Department of Internal Medicine and Biocenter Oulu, University of Oulu, Oulu, Finland
Decreased clearance of low-density lipoprotein in patients with chronic
renal failure. The clearance of low-density lipoprotein (LDL) isolated
from uremic patients (autologous-LDL) and from a control subject
(control-LDL) was studied in 12 uremic patients on conservative
management and compared to the LDL clearance in control subjects.
The clearances of autologous-LDL and control-LDL were almost the
same in the patients. However, the fractional catabolic rate (FCR) of
the autologous-LDL (0.307 0.094 pools/day, mean SD) and the
control-LDL (0.289 0.081 pools/day) were significantly lower (P <
0.05 and P < 0.01, respectively) than the FCR for LDL in the control
subjects (0.376 0.045 pools/day). Moreover, one-half of the patients
had an abnormally low LDL clearance rate ranging from 0.146 to 0.282
pools/day. The FCR for the autologous-LDL varied from 0.146 to 0.416
pools/day between the patients and was negatively related (r =
—0.68,
P = 0.02) to the serum urea concentration (from 11.8 to 39.2 mmollliter)
and tended to correlate positively with the glomerular filtration values
(from 9.2 to 48.3 mllmin/1.73 m2; r = 0.57, P = 0.096, non-linear
relationship). In conclusion, the clearance of LDL in patients with
advanced uremia on conservative management is frequently decreased.
This alteration in the metabolism of the most atherogenic particle in
plasma may contribute to the accelerated atherosclerosis in uremic
patients.
Patients with chronic renal failure have a high frequency of
cardiovascular atheroniatous diseases [1, 2] and lipoprotein
abnormalities. The most prevalent lipid disorders are hypertn-
glyceridemia and decreased high density lipoprotein (HDL)
concentrations [3—7]. Even though the concentrations of the
most atherogenic lipoprotein, low density lipoprotein (LDL),
are usually normal or only marginally increased [3—7), uremic
LDL is qualitatively altered [3, 6, 8, Hörkkö et a!, unpublished
data]. In vitro studies have shown that LDL isolated from
uremic patients is a poor ligand for the LDL apoB/E receptors
[9]. Moreover, LDL isolated from uremic patients on hemodi-
alysis is cleared at a low rate in rabbits [10].
Since LDL particles play an important role in the develop-
ment of atherosclerosis [11, 12], the understanding of LDL
metabolism in chronic renal failure seems to be crucial. The
concentration of LDL in plasma is regulated by two mecha-
nisms: first, the clearance rate (fractional catabolic rate =FCR)
and second, the production rate of LDL apolipoprotein B
(LDL-apoB). To our knowledge, there have been no prior
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studies on the LDL clearance in patients with chronic renal
failure, whereas the very low density lipoprotein (VLDL) apoB
clearance and production has been previously investigated [13].
Therefore, the purpose of this study was to investigate the in
vivo catabolism and production rate of LDL apoB in patients
with uremia. We focused on the following two questions: (1) is
the in vivo clearance of uremic patients' own LDL (autologous-
LDL) altered? and (2) is the in vivo clearance of LDL isolated
from a control subject (control-LDL) altered in uremic pa-
tients?
Methods
Patients and control subjects
Six male and six female patients at different stages of chronic
renal insufficiency in Oulu University Central Hospital volun-
teered for the study. All the patients were on conservative
management (not on any dialysis treatment) and had been
advised to restrict protein (0.8 glkg/day) and phosphate (800
mg/day) intakes. Patients with nephrotic syndrome, diabetes
mellitus, liver disease or thyroid dysfunction were excluded.
Clinical characteristics of the patients are shown in Table 1.
Two of the patients had clinical signs of atherosclerosis: No. 3
had acute myocardial infarction and No. 8 lower limb amputa-
tion due to arteriosclerosis obliterans in the past history. Only
one of the patients (No. 12) was a cigarette smoker. All the
patients gave informed consent for the investigations and the
study protocol was approved by the Ethical Committee of the
Oulu University Medical Faculty.
The control subjects (N = 9) were healthy non-smoker
volunteers. The control-LDL injected into the uremic patients
was isolated in each experiment from control subject No. 2, and
she was free of contagious infections as established by clinical
examination and laboratory tests.
Two of the uremic patients (numbers 1 and 4) received a
kidney transplant after the initial studies, and the LDL turnover
study was repeated one year after the transplantation when the
patients were in a stable condition. Both of these patients
received triple immunosuppressive therapy after the transplan-
tation: Azathioprin (Imurel®, The Wellcome Foundation Ltd.),
Cyclosporine (Sandimmun®, Sandoz) and Methylprednisolon
(Medrol®, The Upjohn Company).
LDL isolation
Fasting venous blood samples were collected into sterile
EDTA-containing tubes and plasma was separated by centrifu-
gation. LDL (d = 1.019 to 1.063 glml) was isolated by repeated
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Table 1. Clinical characteristics of the uremic patients
Serum
Patient
BM
kg/rn2
Urea
mmol/liter
creatinine
smol/iiter
GRF mi/mini
1.73 m2 Diagnosis Drug therapyb
1 22.6 35.6 1258 10.4 Polycystic kidney diltiazem, pindolol, furosemide,
alfacalcidiol
2 21.1 28.0 1132 13.6 Nephrosclerosis
(etiology unknown)
diltiazem, digoxin, furosemide
3 24.3 25.3 993 10,2 chr. glomerulonephritis atenolol, digoxin, furosemide
4 24.1 39.2 884 9.4 chr. pyelonephritis diltiazem, furosemide
5 25.5 22.6 471 11.3 polycystic kidney asebutolol, furosemide
6 21.2 19.1 551 9.2 interstitial nephritis no drug treatment
7 30.1 22.2 316 19.1 chr. glomerulonephritis atenolol, furosemide
8 19.0 25.2 634 13.5 chr. glomerulonephritis furosemide, alfacalcidiol, allopurinol
9 22.3 12,9 233 28.5 chr. glomerulonephritis propranolol, digoxin, prednisolon
10 18.8 16.9 687 11.6 interstitial nephritis metoprolol
11 21.3 11.8 186 48.3 chr, glomerulonephritis labetalol
12 29.4 27.1 1302 11.5 chr. glomerulonephritis metoprolol, minoxidil
Mean 23.3 23.8 721 16.4
(SD) (3.6) (8.2) (391) (11.4)
a Body mass index
b Drugs other than vitamins, phosphate-binding drugs and bicarbonate
ultracentrifugations [14]. The density (d) of plasma was ad-
justed to 1.019 g/ml with sterile NaCl-NaBr solution and the
preparation was ultracentrifuged on a fixed angle rotor (Beck-
man 60 Ti rotor and Beckman L8-60M ultracentrifuge, Beck-
man Instruments, Inc., Palo Alto, California, USA) at 180000 x
g for 18 hours (+ 15°C). The VLDL and IDL-containing fraction
(d < 1.019 gIml) was removed by tube slicing and LDL was
separated from the remaining infranatant by adjusting the
density to 1.063 gIml and ultracentrifuging as described above.
Finally, the LDL was washed in NaCI-NaBr solution (density
1.070 g/ml) 108000 x g in a fixed angle rotor (TFT 40.3 rotor,
Kontron Instruments, Zurich, Switzerland) for 18 hours
(+ 15°C). Before further use the isolated LDL was dialyzed
against 0.15 M NaCI solution containing 0.01% EDTA, pH 7.4
(EDTA-saline). Fresh control-LDL was isolated each time
simultaneously with the autologous-LDL.
lodination of LDL
The LDL for the studies on the control subjects (own LDL)
was iodinated with iodine-125 (1251) (single isotope study). In
the uremic patients the autologous-LDL (patient's own LDL)
and control-LDL (LDL isolated from control subject No. 2)
preparations were iodinated with different isotopes [iodine- 131
(131J) or iodine-125 (1251)] by the iodine monochloride method of
McFarlane [15] as modified by Bilheimer et al [16]. Excess free
radioiodine was removed by a column chromatography (Phar-
macia Columns PD-b Sephadex G-25M, Pharmacia, Uppsala,
Sweden) and EDTA-saline dialysis. Precipitation with 10%
trichioroacetic acid (TCA) showed that 97.4 (2. 1)% [mean (SD)]
of 131! counts and 94.2 (2.2)% of 125J counts were bound to
protein. The extent of lipid labeling was determined with a
chloroform-methanol solvent (2:1) using the method of Folch et
al [17]. The lipid labeling averaged 10.7 (4.1)% [mean (su)] for
131j and 8.1 (2.l)% for l2Sj
Preparation of LDL and the patients for the in vivo injection
After dialysis radiolabeled autologous-LDL and control-LDL
preparations were centrifuged at 3300 x g for 10 minutes (+4°C)
and the supernatant was passed through a 0.22 tm Millipore
filter. An amount of 10 to 20 pCi of both preparations were
mixed together with 5% human serum albumin (Finnish Red
Cross, Helsinki, Finland) and the final solution was again
passed through a 0.22 m Millipore filter. The patients were
given potassium iodide (KI) 200 mg/day orally one day before
and throughout the study to block native thyroid uptake of
radioactive iodine.
Study protocol and sample analysis
The preparations containing radiolabeled autologous-LDL
and control-LDL were injected intravenously into the uremic
patients after an overnight fast. Ten to 20 ml blood samples
were obtained at 0, 15, 30 minutes, 1, 2, 3 hours and three times
a week for 14 days thereafter. The plasma total radioactivity
was determined in each sample in a LKB Wallac 1282 Corn-
pugamma Universal Gammacounter (Wallac Oy, Turku, Fin-
land). LDL fractions from all plasma samples of the first three
patients (numbers 1, 4 and 11, respectively) were isolated by
ultracentrifugation as described below. The isolated LDL frac-
tions were dialyzed in EDTA-saline and the radioactivities were
determined. A total of 92.7 (1 .9)% of the autobogous-LDL
[mean (SD)] and 94.4 (1 .4)% of the control-LDL up to three
hours, and 88.9 (4.2)% of the autologous-LDL and 91.5 (2.8)%
of the control-LDL from three hours to seven days, and 78.4
(7. 1)% of the autologous-LDL and 83.8 (5 .9)% of the control-
LDL from seven to fourteen days after the injection flotated
within the originally isolated LDL density region. The frac-
tional catabolic rates calculated for the plasma decay curves
and for the decay curves of the LDL fractions differed less than
8%. For the first two patients (Nos. 1 and 4) aliquots of plasma
samples up to four days were precipitated with 10% TCA to
demonstrate whether or not the radiolabel remained protein-
bound in plasma. Over 90% of both 125! and 131J counts were
TCA-insoluble.
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Kinetic analysis
The clearance rates (the fractional catabolic rate, FCR,
defined as the intravascular pool of LDL catabolized per hour)
for the autologous-LDL and the control-LDL were calculated
from the plasma decay curves using the method described by
Matthews [18] and by Nosslin [19], and later adapted for LDL
turnover studies by Langer, Strober and Levy [20]. In brief,
two exponential equations were fitted to each plasma decay
curve using an interactive curve-peeling program (W.F. Beltz
and T.E. Carew, unpublished method) on a VAX-VMS Com-
puter. The LDL production rates were calculated from the
fractional catabolic rates of the autologous LDL, pool volumes
and apolipoprotein B concentrations, and expressed as milli-
grams per kilogram body weight per day.
The LDL-apoB clearance rates for the control subjects were
obtained in a study where their own LDL was isolated, radio-
labeled and injected intravenously, and the FCR was calculated
from the plasma decay curves as described above.
Reproducibility of the LDL clearance method
To test the reproducibility of the LDL clearance LDL was
isolated from a healthy volunteer, labeled with 1251, injected
back into the donor and the LDL clearance rate was calculated
as described above. The LDL clearance study was repeated
identically in the same volunteer after two months. The FCR for
LDL was 0.330 pools/day in the first study and 0.344 pools/day
in the second study. The plasma total and LDL cholesterol
concentrations of the volunteer varied between 5.4 to 5.8
mmollliter and 2.5 to 3.6 mmol/liter, respectively, and plasma
total triglyceride concentration between 1.8 to 2.4 mmollliter
during both experiments.
Lipoprotein fractionation for the lipoprotein analysis
VLDL, intermediate density lipoprotein (IDL), LDL and
high density lipoprotein (HDL) fractions from the plasma
samples of the patients and the control subjects were isolated
by repeated ultracentrifugations [141 using appropriate density
adjustments with NaC1-NaBr solutions and the fixed angle TFT
rotor at 108000 X g (+ 15°C) for 18 hours (VLDL, IDL and LDL
fractions) and for 48 hours (HDL fraction).
To correct the lipoprotein losses in LDL and HDL fractions
during the repeated ultracentrifugations, the VLDL fraction
was first isolated from a separate simultaneous plasma sample
as described above and HDL cholesterol was measured from
the remaining infranatant (VLDL-infranatant) after precipita-
tion of IDL and LDL with heparin-manganese [21]. LDL
cholesterol was calculated by subtracting the HDL and the IDL
cholesterol from the total cholesterol content of the VLDL-
infranatant. Cholesterol, triglyceride and protein concentra-
tions in LDL and HDL fractions were then corrected by the
ratio of the LDL (or HDL) cholesterol concentration measured
with heparin-manganese precipitation to the LDL (or HDL)
cholesterol concentration measured after repeated ultracentnf-
ugations.
Lipid and protein analysis
Cholesterol and triglyceride concentrations were determined
with enzymatic colorimetric methods (kits of Boehringer Diag-
nostica, Mannheim GmbH, Germany, cat. nos. 236691 and
701912, respectively) using a Gilford IMPACT 400E Clinical
Chemistry Analyzer (Gilford Instruments Laboratories Inc.,
Oberlin, Ohio, USA). The protein contents of the various
lipoprotein fractions were measured by the method of Lowry et
al [22] and the amount of apolipoprotein B was determined after
isopropanol precipitation [23].
Lipoprotein (a) analysis
Plasma lipoprotein (a) [Lp(a)] concentrations were measured
by a two-site radioimmunometric assay (2-site IRMA) using two
different monoclonal antibodies in excess (Pharmacia Diagnos-
tica AB, Uppsala, Sweden). The radioactivities were deter-
mined with a LKB Wallac 1282 Compugamma Universal Gam-
macounter (Wallac Oy, Turku, Finland). The conversion factor
of 1 unit of Apo(a) equal to 0.7 mg Lp(a) was used.
Urea, creatinine and glomerular filtration measurements
The serum urea and creatinine concentrations were deter-
mined with standard methods in the routine laboratory of the
Oulu University Central Hospital. The renal function was
estimated as glomerular filtration rates (GFR) measured with
mTc-DTPA. GFR values obtained with mTc-DTPA method
have previously been shown to correlate extremely well (r =
0.97) with the values obtained by the inulin clearance method
[24].
Statistical analysis
The statistical significances were calculated using Student's
t-test and the coefficients of correlation were analyzed with
linear (Pearson) and non-linear (Levenberg-Marquardt) regres-
sion analysis.
Results
Plasma lipids and lipoproteins
The cholesterol and triglyceride concentrations in plasma and
in various lipoprotein fractions of the patients and the control
subjects are shown in Table 2. The uremic patients tended to
have increased plasma total, VLDL, IDL and decreased HDL
cholesterol concentrations and increased plasma total, VLDL,
IDL, LDL and HDL triglyceride concentrations compared to
the control subjects. The serum urea concentration of the
patients was positively related to the cholesterol concentrations
in total plasma (r = 0.62, P = 0.03) and VLDL (r = 0.88, P =
0.0002), IDL (r = 0.63, P = 0.03) and LDL (r = 0.62, P = 0.03)
fractions. The HDL cholesterol, however, was not related to
the serum urea levels. The serum urea concentration was
positively related to the triglyceride concentrations in total
plasma (r = 0.82, P = 0.001) and VLDL (r = 0.73, P = 0.007),
IDL (r = 0.71, P = 0.01), LDL (r = 0.88,P = 0.0001) and HDL
(r = 0.72, P = 0.009) fractions (Fig. 1).
Clearance and production rates of LDL apolipoprotein B
The clearance (fractional catabolic rates = FCR) and the
production rates and concentrations of LDL apolipoprotein B
for the patients and the control subjects are shown in Table 3.
No significant differences were observed in the apolipoprotein
B concentrations in the VLDL, IDL and LDL fractions be-
tween the uremic patients and the control subjects (Table 3). A
positive relation, however, was found between the serum urea
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Table 2. Plasma total, lipoprotein lipid and Lp(a) concentrations of the uremic patients and the control subjects
Cholesterol mmol/1 Triglycerides mmol/l Lp(a)
mg/dlTotal VLDL IDL LDL HDL Total VLDL IDL LDL HDL
Patients
1 8.04 1.74 0.99 4.00 1.28 2.49 1.41 0.21 0.69 0.26 135
2 6.70 0.79 0.25 3.61 1.82 1.86 0.98 0.11 0.37 0.24 21
3 3.72 0.53 0,20 1.90 0.66 2.05 0.91 0.07 0.41 0.23 20
4 6.78 1.71 0.75 3.25 0.94 2.65 1.42 0.25 0.81 0.29 87
5 5.34 0.73 0.43 2.60 1.00 2.13 1.22 0.10 0.31 0.20 21
6 3.58 0.42 0.19 1.70 0.98 1.17 0.53 0.05 0.16 0.15 1
7 4.44 0.56 0.36 2.05 1.01 1.61 0.71 0.10 0.32 0.24 13
8 4.85 0.42 0.47 2.49 1.38 0.98 0.14 0.01 0.24 0.14 46
9 6,14 0.38 0.50 2.82 1.80 1.22 0.56 0.12 0.20 0.06 5
10 4.10 0.63 0.48 1.76 1.23 1.35 0.54 0.04 0.19 0.16 54
11 3.75 0.18 0.16 1.99 1.12 0.76 0.25 0.05 0.17 0.15 12
12 4.26 0.70 0.40 1.92 1.10 1.42 0.57 0.07 0.25 0.22 4
Mean 5.14 0.73 0.43 2.51 1.19 1.64 0.77 0.10 0.34 0.21 35
(Sn) (1.46) (0.49) (0.24) (0.79) (0.34) (0.60) (0.42) (0.07) (0.21) (0.07) (40)
Controls
1 4.62 0.21 0.12 2.30 1.92 0.75 0.27 0.06 0.18 0.12 4
2 4.45 0.18 0.07 2.10 1.65 0.75 0.34 0.04 0,15 0.17 31
3 5.84 0.85 0.20 3.13 1.29 1.59 0.75 0,05 0.52 0.27
4 5,70 0.55 0.29 3.62 1.28 1.30 0,68 0.10 0.37 0.12
5 4.52 0.28 0.13 3.02 1.41 0.94 0.47 0.08 0.19 0.16 1
6 5.67 0.27 0.12 3.78 1.54 0.97 0.26 0.10 0.39 0.18
7 5.21 0.71 0.23 2.44 1.39 1.04 0.61 0.11 0.22 0.14
8 2.29 0.22 0.10 1.17 0.91 0.59 0.22 0.08 0.25 0,07
9 5.06 0.40 0.12 2.42 1.56 0.98 0.46 0.03 0,15 0.12
Mean 4.82 0.41 0.15 2.66 1.44 0.99 0.45 0.07 0.27 0.15
(SD) (1.08) (0.24) (0.07) (0.81) (0.28) (0.30) (0.19) (0.03) (0.13) (0.06)
Figures are mean values of determinations from at least three separate samples taken on different days during this study.
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Fig. 1. The relationship between the serum
urea concentrations and plasma total, VLDL
LDL and HDL triglyceride (TG) concentrations
in the twelve uremic patients.
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Table 3. The clearance and production rates and concentrations of LDL apolipoprotein B for the uremic patients and the control subjects
Sex Age
FCR pools/day LDL apoB
production
mg/kg/day
ApoB mg/dl
Autologous-LDL Control-LDL VLDL IDL LDL
Patients
1 M 53 0.146 0.166 11 19 15 114
2 F 64 0.211 0.210 20 4 8 135
3 M 64 0.216 0.212 7 10 4 50
4 F 43 0.229 0.205 12 24 14 100
5 F 40 0.267 0.239 6 11 6 57
6 M 31 0.282 0.274 7 7 2 39
7 F 48 0.334 0.310 7 10 6 51
8 F 61 0.367 0.369 16 3 5 65
9 M 72 0.387 0.358 12 6 7 80
10 F 37 0.390 0.395 12 7 6 49
11 M 48 0.416 0.377 12 2 3 54
12 M 47 0.435 0.351 16 9 9 77
Mean 51 0.307 0.289 12 9 7 72
(SD) (12) (0.094) (0.08!) (4) (6) (4) (30)P <o.osa <001b
Controls
1 M 32 0.318 9 3 2 45
2 F 24 0.319 10 6 3 60
3 M 58 0.347 15 84
4 M 64 0.360 11 8 5 68
5 M 40 0.366 13 7 4 100
6 F 80 0.386 14 99
7 M 54 0.412 14 56
8 M 77 0.435 7 32
9 M 45 0.437 12 53
Mean 55 0.376 12 6 4 66
(SD) (20) (0.045) (3) (2) (1) (24)
Abbreviation FCR is fractional catabolic rate.
ap < 0.05 uremic patients versus control subjects
b p < 0.01 uremic patients versus control subjects
FCR = 0.211 POOLS/D
FCR = 0.267 POOLSID
FCR = 0.334 POOLS/D
FCR = 0.435 POOLS/D
0 2 4 6 8 101214 0 2 4 6 8 10 12 1416
Time, days
Fig. 2. Plasma decay curves for the auto!ogous-LDL () and the
contro!-LDL (I) infour uremic patients (Nos. 2, 5, 7 and 12. from the
upper left panel to the lower right panel, respectively). FCR =
fractional catabolic rate.
pools/day, mean SD) and the control-LDL (0.289 0.081
pools/day) did not significantly differ from each other, but were
significantly lower (P = 0.05 and P = 0.009, respectively) than
the FCR values for the LDL-apoB of the control subjects (own
LDL) (0.376 0.045 pools/day) (Table 3). Furthermore, there
was an over twofold variation in the FCR for the autologous-
LDL (from 0.146 to 0.416 pools/day) and the FCR for the
control-LDL (from 0.166 to 0.395 pools/day) between the
patients. The FCR values for autologous-LDL and control-
LDL in six patients (Nos. 1 to 6) were abnormally low (from
0.146 to 0.282 pools/day). On the other hand, the FCRs for the
six remaining patients (Nos. 7 to 12) (from 0.334 to 0.435
pools/day) were within the range of the FCRs for the control
subjects. Overall, this variation in the FCR for LDL in the
uremic patients was negatively related to the serum urea
concentration (r =
—0.68, P = 0.02; Fig. 3). The relation
1etween the FCR for the LDL and the serum creatinine
concentration did not quite reach statistical significance (Fig.
3). The glomerular filtration rates also tended to be related to
the FCR for the autologous-LDL (r = 0.57, P = 0.096) and the
control-LDL (r = 0.58, P = 0.099) but in a non-linear fashion
(Fig. 4). The FCR for the autologous-LDL was also negatively
related to the plasma total (r =
—0.59, P = 0.05), LDL (r =
—0.64, P = 0.02) and VLDL (r = —0.67, P = 0.02) cholesterol
concentrations and to the plasma total, VLDL, IDL, LDL and
HDL triglyceride, concentrations (r =
—0.81, P = 0.001; r =
—0,81, P = 0.001; r = —0.60, P = 0.04; r = —0.73, P 0.008;
r =
—0.65, P = 0.02, respectively; Fig. 5). The FCR for the
autologous-LDL was also negatively related to the VLDL
apolipoprotein B (r —0.60, P = 0.04) but not IDL or LDL
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apoB concentrations. Similar correlations were also observed
between the lipoprotem lipids and the FCR values for the
control-LDL in the patients (data not shown).
The LDL-apoB production rates of the uremic patients (12
4 mg/kg/day, mean SD) were equal to those of the control
0.5 subjects (12 3 mg/kg/day; Table 3). Moreover, the LDL-apoB
production rates were related to the LDL-apoB concentrations
0.4 (r = 0.64, P = 0.03) and HDL cholesterol concentrations (r =
0.71, P 0.009), but not VLDL, IDL or LDL cholesterol
0.3 concentrations.
Comparison of the patients with low LDL and high LDL
There were no significant differences in the age, sex, BMI,
diagnosis or the drug therapy between the patients with low
LDL clearance (Nos. ito 6) (FCR for autologous-LDL 0.225
0.048 pools/day, mean SD) and the patients with normal LDL
clearance (Nos. 7 to 12) (FCR for autologous-LDL 0.388
0.036 pools/day; Tables 1 and 3). However, the patients with
low LDL clearance had significantly higher serum urea concen-
trations (28.3 7.7 mmol/liter, mean si, P 0.05) and
tended to have higher serum creatinine concentrations (884
315 prnol/liter) and lower glomerular filtration rates (10.7 1.6
mI/mm/i .73 m2) than the patients with normal LDL clearance
(19.4 6.4 mmollliter, 560 416 moIJliter, 22.1 14.4
ml/min/i.73 m2, respectively; Table 1).
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Fig. 3. The correlations between the serum urea and the serum creat-
mine concentrations and the fractional catabolic rates (FCR) for the
autologous-LDL () and the control-LDL (•) in the twelve uremic
patients.
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Fig. 4. Relation between the glomerular filtration rate (GFR) and
fractional catabolic rate (FCR) for the autologous-LDL () and the
control-LDL (•) in the twelve uremic patients.
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Patien
Before
t No. 1
After
Patien
Before
t No. 4
After
Weight kg 70 71 61 74
Serum urea mmol/liter 35.6 14.9 39.2 3.8
Serum creatinine pmol/liter 1258 110 884 108
GRF ml/min/1.73 m2 10.4 39.8 9.4 62.3
Cholesterol mmol/liter
Plasma total 8.04 7.13 6.78 6.57
VLDL 1.74 0.75 1.71 0,77
IDL 0.99 0.51 0.75 0.50
LDL 4.00 4.16 3.25 4.01
HDL 1.28 1.63 0.94 0.99
Triglyceride mmol/liter
Plasma total 2.49 1.92 2.65 2.09
VLDL 1.41 0.99 1.42 1.21
IDL 0.21 0.15 0.25 0.18
LDL 0.69 0.33 0.81 0.41
HDL 0.26 0.24 0.29 0.17
Lp(a) mg/dl 135 118 87 46
FCR pools/day
Autologous-LDL 0.146 0.263 0.229 0.226
Control-LDL 0.166 0.264 0.205 0.216
LDL apoB production
mg/kd/day 11 16 12 12
mg/day 770 1165 732 879
VLDL apoB mg/dl 19 16 24 17
IDL apoB mg/dl 15 12 14 11
LDLapoBmg/dl 114 119 100 114
the kidney transplantation
Table 4 shows the lipoprotein profiles and the clearance and
production rates for LDL-apoB before and after the transplan-
tation in the two patients (Nos. 1 and 4) who received a kidney
transplant. A minor decrease was observed in the plasma total
cholesterol (11% and 3%, patients 1 and 4, respectively) and a
distinct decrease in the plasma total triglyceride concentrations
(23% and 21%) in both patients after the transplantation. The
reductions in the total cholesterol levels were due to markedly
decreased VLDL (57% and 55%, patients 1 and 4, respectively)
and IDL cholesterol concentrations (48% and 33%). In contrast,
LDL (4% and 23%) and HDL (27% and 5%) cholesterol
concentrations were increased in both patients after the trans-
plantation. The triglyceride concentrations were reduced in
each fraction, mostly in VLDL (30% and 15%, patients 1 and 4,
respectively), IDL (29% and 28%) and LDL (52% and 49%).
Also, the apoB concentrations were decreased in VLDL, IDL
and LDL fractions after the transplantation (Table 4).
In patient No. 1, the FCR for the autologous-LDL was
increased by 80% (from 0.146 to 0.263 pools/day), and that for
the control-LDL by 59% (from 0.166 to 0.264 pools/day) after
the transplantation (Fig. 6). No significant changes were de-
tected in the fractional catabolic rates of patient number 4 after
the transplantation (Fig. 6).
Lipoprotein (a)
The Lp(a) levels of the patients are shown in Table 2. The
patients with low LDL clearance tended to have higher Lp(a)
concentrations (mean SD 47 52 mg/dl, median 21 mg/dl)
than the patients with normal LDL clearance (mean SD 35
40 mg/dl, median 13 mg/dl; P = 0.7). However, the Lp(a) levels
were not related to the LDL clearance rates. On the other hand,
the Lp(a) levels were related to the plasma total (r = 0.69, P =
0.01), VLDL (r = 0.86, P = 0.0004), IDL (r = 0.88, P = 0.0001)
and LDL (r = 0.66, P = 0.02) cholesterol concentrations and
plasma total (r = 0.62, P = 0.03), VLDL (r = 0.58, P = 0.05),
IDL (r = 0.66, P = 0.02) and LDL (r = 0.78, P = 0.003)
triglyceride concentrations and serum urea concentrations (r =
0.68, P = 0.01), but not to serum creatinine (r = 0.45, P = 0.14)
or glomerular filtration rate values (r =
—0.33, P = 0.30). After
the kidney transplantation the Lp(a) levels of the patient
number 1 decreased from 135 to 118 mg/dl (12.6%) and in the
patient number 4 from 87 to 46 mg/dl (47.1%) (Table 4).
Discussion
The major finding of the present study is that the clearance of
LDL is frequently decreased in patients with uremia on con-
servative management. Furthermore, the rate of LDL clearance
is related to the serum urea levels of the patients.
In the literature, the fractional catabolic rate for LDL-apoB
documented for normal subjects ranges from 0.287 to 0.462
pools/day (mean 0.371 pools/day), and LDL-apoB production
ranges from 7.7 to 14.4 mg/kg/day (mean 11.4 mg/kg/day) [25].
Our control subjects had fractional catabolic rate (from 0.318 to
0.437, mean 0.376 pools/day) and production rate (from 7 to 15,
mean 12 mg/kg/day) values for LDL-apoB exactly as those
reported in the literature. However, six out of the twelve
uremic patients had low to extremely low LDL clearance rates,
the FCRs ranging from 0.146 to 0.282 pools/day. Normally, this
low LDL clearance rates are observed only in hetero- or
homozygous patients with familial hypercholesterolemia [25].
The FCRs for the six remaining patients (from 0.334 to 0.435
pools/day) were well within the range documented for normal
subjects in the literature (see above). The apolipoprotein B
Table 4. Plasma lipids and lipoproteins and LDL apolipoprotein B
clearance and production rates of the two patients before and after
the kidney transplantation
A Patient no. 1 B Patient no. 4
FCR = 0.146 POOLS/DV
U) 1.0.
C.)
U)
ci)
Ci)0V
0
go.i
C)
cci
U-
Time, days
Fig. 6. Plasma decay curves for the autologous-LDL of the two kidney
transplant patients (Nos. 1 and 4) before () and after (•) the kidney
transplantation. FCR = fractional catabolic rate.
0 4 8 12 0 4 8 12 16
The figures of the lipid concentrations are mean values of determi-
nations from at least three separate samples taken on different days
during the study.
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production rates for eight uremic patients were in the normal
range (from 7 to 12 mg/kg/day), one subject having lower (6
mg/kg/day) and three having higher values (from 16 to 20
mg/kg/day) than those documented for normal subjects in the
literature.
The decreased clearance of LDL in uremic patients could be
due to several mechanisms. For example, the LDL particles in
uremic patients might be altered in such a way that the
interaction with LDL apoB/E receptors is disturbed. In fact, we
and other workers have previously observed that LDL isolated
from uremic patients [10] and from experimental uremic guinea
pigs [26] is cleared in vivo at a slow rate, suggesting that there
might be abnormalities in the LDL-particles. One explanation
for the LDL particle-related defect in the clearance could be the
modification of LDL apolipoprotein B, for example, with car-
bamyl-groups. This is supported by the findings that carbamy-
lated LDL has decreased binding to the LDL receptors [9, 10,
27] and decreased clearance in vivo [10]. Another explanation
for the finding that the uremic LDL particles are cleared at a
slow rate could be the altered chemical composition, that is,
triglyceride enrichment, of LDL. It has been documented that
triglyceride-rich LDL is poorly catabolized by human fibro-
blasts [28—30]. Moreover, the triglyceride content of the core of
the LDL particles has been shown to affect the conformation of
LDL receptor binding domains of apolipoprotein B and,
thereby, the lipoprotein-cell interaction [31]. Both of these
possibilities are supported by the finding that the fractional
catabolic rates for LDL-apoB were highly related to the serum
urea concentrations and the LDL triglyceride concentrations of
the uremic patients. However, these hypotheses are opposed
by our findings that the clearance rates of LDL isolated from a
healthy control subject were almost similar or even somewhat
lower (in eight patients out of twelve) than the clearance rates of
LDL isolated from the uremic patients. The alterations in the
LDL particles in uremia, therefore, may not explain the low
clearance of LDL. On the other hand, we cannot exclude the
possibility that the control-LDL particles are rapidly altered,
for example, by the transfer proteins [32, 33] after they have
been injected into uremic patients.
In addition to the particle-related impairment of LDL clear-
ance other theoretical mechanisms for the decreased LDL
catabolism, such as alterations in LDL apoB/E receptors, must
be considered. First, patients with familial hypercholesterol-
emia (FH) have genetic defects in the LDL receptor gene and
the LDL receptors cannot bind or internalize LDL particles.
Therefore, the fractional catabolic rates for LDL are low in
patients with heterozygous (0.237 0.044 pools/day, mean
SD) [25] and particularly homozygous FH (0.176 0.040
pools/day) [34]. The fractional catabolic rate for LDL in one
uremic patient (0.146 pools/day, patient No. 1) was similar to
that of the patients with homozygous FH and the fractional
catabolic rate for LDL in five uremic patients (from 0.211 to
0.282 pools/day) were similar to those of the patients with
heterozygous FH. These uremic patients with low FCRs did
not, however, have FH since the LDL cholesterol levels of
these patients were close to normal (from 1.70 to 3.61 mmoli
liter) and no clinical signs of FH were observed. Moreover, the
extremely low FCR value in one uremic patient was increased
after the transplantation (from 0.146 to 0.263 pools/day). Fur-
ther differences between the uremic patients with low FCR and
patients with FH are that the LDL-apoB concentrations (82.5
39.1 mg/dl) and production rates (10.5 5.2 mg/kg/day) of the
uremic patients were lower than those documented for the
patients with heterozygous (126 21 mg/dl and 13.8 3.6
mg/kg/day, respectively) and homozygous (362 126 mg/dl and
26.4 10.0 mg/kg/day, respectively) FH [34].
Second, another LDL receptor-related mechanism for the
decreased LDL clearance in uremic patients could be that LDL
receptors, instead of the LDL particles themselves, are post-
translationally modified, for example, carbamylated and cannot
therefore bind and process LDL particles. This possibility
remains to be explored.
Third, a recent study showed that LDL apoB/E receptor
function and mRNA expression are decreased in lymphocytes
isolated from uremic patients [35]. This suggests that uremic
patients have a lowered amount of LDL receptors due to either
a transcriptional defect, reduced LDL receptor mRNA stability
or increased LDL receptor mRNA degradation [35]. The level
of dysfunction in the lymphocyte assay [35] was also similar to
that seen in patients with familial hypercholesterolemia. Thus,
this mechanism seems to offer an acceptable explanation for the
decreased LDL clearance observed in our uremic patients.
Previous studies have demonstrated that the liver is mainly
responsible for the clearance of LDL in animal species such as
rat and hamster (from 55 to 75%) [36]. The small intestine is the
second most important site for LDL degradation, whereas the
role of the remaining organs of the body is very small [36]. Also,
the role of the liver in the LDL clearance in humans has been
established in an experiment where the LDL clearance was
determined from an FH homozygous patient before and after a
liver-heart transplant [37]. The LDL clearance before the
transplantation was only 0.12 pools/day and after the operation
0.31 pools/day [37]. Calculations from the liver transplant
experiment suggest that the hepatic LDL receptors can clear
about 61% of the plasma LDL [38]. Therefore, according to
these previous studies the role of the kidney in the LDL
clearance seems to be relatively small. Overall, it is unlikely
that the extremely low LDL clearance rates observed in the
uremic patients could be explained by the changes in the renal
extraction of LDL. However, this question has not been
specifically addressed.
Lipoprotein (a) is a plasma lipoprotein with density distribu-
tion of 1.050 to 1.120 g/ml [39—42]. The protein moiety of Lp(a)
consists of highly glycosylated apo(a) which is covalently
bound to the LDL apolipoprotein B [39—42]. Several studies
have suggested that elevated plasma Lp(a) levels are athero-
genic [43—45]. Moreover, patients with chronic renal failure
have been shown to have higher Lp(a) levels compared to
control subjects [46—50] and elevated Lp(a) concentrations have
been demonstrated to be an independent risk factor for cardio-
vascular disease also in hemodialysis patients [51]. We also
studied the Lp(a) levels of the patients since the LDL fractions
(density 1.019 to 1.063 g/ml) may contain some amounts of
Lp(a) [39—42]. Overall, in our experiments the LDL clearance
rates were not related to the Lp(a) concentrations. Moreover,
the LDL clearance was increased by 80% after the kidney
transplantation in the patient number 1 without any marked
change in Lp(a) levels (135 and 118 mg/dl, before and after the
transplantation, respectively), whereas in the patient number 4
the LDL clearance did not change after the transplantation but
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the Lp(a) concentration was decreased by 47% (from 87 to 46
mgldl).
In conclusion, we have demonstrated that the LDL clearance
is often abnormally low in patients with chronic renal failure.
The delayed LDL clearance results in an increase in the
residence time of LDL in the circulation. This may lead to a
number of disturbances in LDL metabolism, for example,
modifications of LDL, such as the carbamylation, oxidation or
interaction with glycosaminoglycans suggested to accelerate
atherosclerosis [10, 52, 53]. The results of the present study
were focused on uremic patients on conservative management.
Many of the uremic patients, however, are treated with hemo-
dialysis or continuous ambulatory peritoneal dialysis and fur-
ther information on the LDL metabolism in uremic patients on
various types of treatment is urgently needed.
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